M1742 Colitis Induces Calcitonin Gene-Related Peptide (CGRP) Expression and AKT Activation in Rat Primary Afferent Pathways

2009 ◽  
Vol 136 (5) ◽  
pp. A-422
Author(s):  
Li-Ya Qiao ◽  
John R. Grider
1990 ◽  
Vol 109 (1-2) ◽  
pp. 76-81 ◽  
Author(s):  
Susan M. Carlton ◽  
Karin N. Westlund ◽  
Dongxian Zhang ◽  
Linda S. Sorkin ◽  
William D. Willis

1997 ◽  
Vol 273 (1) ◽  
pp. G191-G196 ◽  
Author(s):  
V. Plourde ◽  
S. St-Pierre ◽  
R. Quirion

The role of calcitonin gene-related peptide (CGRP) on colorectal distension-induced visceral pain was investigated in conscious rats. Intracolonic administration of acetic acid (0.6%) resulted in a significantly increased number of abdominal contractions in response to colorectal balloon distension from 5.8 +/- 1.2 in controls to 16.6 +/- 1.0 in acetic acid-treated animals (P < 0.05), evidencing sensitization of visceral afferent pathways and subsequently visceral hyperalgesia. This sensitization phenomenon was not observed in animals previously treated with systemic capsaicin. Likewise, in animals not treated with capsaicin, use of an intravenous antagonist for CGRP [human CGRP-(8-37)], completely reversed the sensitizing effects of acetic acid. Furthermore, intravenous administration of CGRP dose dependently increased the number of abdominal contractions in response to colorectal distension from 3.0 +/- 1.1 (CGRP 250 ng) to 17.0 +/- 1.2 (CGRP 500 ng, P < 0.05), as previously observed in acetic acid-treated animals. Finally, intrathecal administration of hCGRP-(8–37) (mid-lumbar) also resulted in a total dose-dependent reversal of CGRP (500 ng) or acetic acid-induced visceral hypersensitivity. These results demonstrate that CGRP plays a major role in this model of visceral afferent nerve sensitization from gastrointestinal origin.


1995 ◽  
Vol 73 (7) ◽  
pp. 1007-1014 ◽  
Author(s):  
V. S. Seybold ◽  
M. T. Galeazza ◽  
M. G. Garry ◽  
K. M. Hargreaves

Injection of complete Freund's adjuvant (CFA; 75 μL) into the plantar surface of the hind paw of the rat results in a mild inflammation that lasts for several days and is accompanied by hyperalgesia. Multiple components of calcitonin gene related peptide (CGRP) neurotransmission in the spinal cord are altered during the course of this peripheral inflammation. The content of immunoreactive (i) CGRP in the dorsal horn of the spinal cord, where primary afferent neurons terminate, is significantly decreased within 2 days after injection of CFA but increases to a level greater than that of the control at 8 days. The early decrease in iCGRP in the spinal cord suggests that the release of CGRP from primary afferent neurons is increased during the period of maximal hyperalgesia that accompanies peripheral inflammation. Changes in the mRNA for CGRP suggest that the increase in spinal content of iCGRP is due to an increase in synthesis of the peptide as the level of mRNA for CGRP is increased from 2 to 8 days after injection of CFA. Despite the decrease in the content of iCGRP in the spinal cord, there is no apparent decrease in the amount of iCGRP that can be released from the dorsal spinal cord by capsaicin; in fact, capsaicin-evoked release is increased at 4 days. Measurements of the binding of 125I-labelled CGRP in the dorsal spinal cord indicate that high affinity binding sites for CGRP are downregulated at 4 days after injection of CFA. In total, these data support the hypothesis that the activity of CGRP-containing primary afferent neurons is increased during peripheral inflammation. CGRP released from primary afferent neurons in the spinal cord may contribute to cellular changes that accompany peripheral inflammation.Key words: calcitonin gene related peptide, dorsal root ganglion, hyperalgesia, inflammation, spinal cord.


Sign in / Sign up

Export Citation Format

Share Document